Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
OncoTherapy Science EBITDA Margin % Related Terms
OncoTherapy Science EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:30O vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, OncoTherapy Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (FRA:30O) has a EBITDA Margin % of -93.91% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoTherapy Science and its competitors. According to the industry distribution chart, OncoTherapy Science ranks #511 out of 940 companies in the Biotechnology industry, placing it in the top 54.4%.
Is OncoTherapy Science's EBITDA Margin % too high?
OncoTherapy Science's current EBITDA Margin % is -93.91%. Based on the distribution chart, OncoTherapy Science ranks #511 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #511 out of 940 companies for EBITDA Margin %. This places OncoTherapy Science in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current EBITDA Margin % is -93.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 3.1% above its estimated fair value. The current EBITDA Margin % is -93.91%. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current EBITDA Margin % is -93.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (FRA:30O) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of €0.08 is trading 3.1% above its estimated GF Value™ of €0.08.
GuruFocus considers OncoTherapy Science to be Fairly Valued.
Key valuation signals for FRA:30O:
EBITDA Margin %: -93.91%
GF Value™: €0.08 vs. price of €0.08 (3.1% above fair value)
No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for FRA:30O
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:30O has been successfully added to your 
